CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea

Gastro Hep Advances · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles